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1 Supplementary Figures 
 
Supplementary Figure 1: Cryo-Transmission Electron Microscopy. Cryo-









Supplementary Figure 2: (a) Crystal structure (pdb: 1qbe) of a Qβ capsid. The hexagon 
and pentagon substructures are indicated as gray lines. The anchoring points of the Sia units 





in a hexagon-hexagon substructure. (d) Sia duplets in a hexagon-pentagon substructure, 
whereby the initial Sia is found in the hexagon substructure. (e) Sia duplets in a hexagon-
pentagon structure, whereby the initial Sia is found in the pentagon substructure. (f) Sia 
duplets in a hexagon-hexagon substructure. (g) An unbound monovalent Sia (bottom) can 
freely rotate around all axes in space, which leads to an angular space of 8π2. The steric 
restrictions due to the presence of the EG linker (top) reduce the angular space to ΩSia. (h) 
Schematic picture of the position and orientation of the Qβ capsid. The vector rQβ denotes 
the position of the Qβ capsid (green) relative to the HA trimer (blue), while the capsid 
orientation is quantified by the Euler angles ϕ,θ,ψ. The Sia units are indicated as red half 
spheres and the EG linkers as purple lines. (i) Dissociation constant (Eq.11) for varying 
𝐾mono. The cooperativity factor 𝐶3 as well as the angular restriction factor 𝜔sia are the same 
in all three cases. (j) The inverse of the dissociation constant (Eq. 10) is shown together with 
the contribution from mono-, di- and trivalently bound Qβ capsids. The edge lengths (d1, d2 
and d3) of the Sia triplets are indicated in the legend. (k) Illustration of the arrangement of 
Qβ capsids on the virus surface for the minimal (left) and maximal (right) number of capsids 
per virus. (l) Schematic picture of the contact between a deformable virus and a spherical 
Qβ capsid. (m) Illustration of the Euler angles at the connection between the Sia unit and the 
EG linker. (n) Scatterplot of the Euler angles from an MD simulation of a Sia unit connected 
to an EG linker in water. (o) The stretching probability Pstr, obtained from MD simulations, 
of all ten EG oligomers is shown in dependence of the end-to-end distance 𝒓𝒆𝒕𝒆. 
 
 
Supplementary Figure 3. Human lung tissue infection experiments and production of TNF-
α, IL1-β and IFNβ. Experiments were conducted either with Qβ capsids, which were purified 
in a standard procedure (a-c) or additionally purified capsids (indicated with *) using an 
endotoxin removal procedure (d-f). For 10 nM Qβ[Sia1], as used in the lung experiments, 





assay for phage capsids from a standard purification, and no endotoxin could be detected 
after endotoxin removal (detection limit <1 EU/ml). 1 EU/ml corresponds to 0.1-0.2 ng/ml 
LPS equivalents. LPS (10 ng/ml) was used as positive control for the stimulation of innate 
immunity. Cytokine levels were measured using an ELISA 48 h after stimulation of tissue 
with the indicated materials. Error bars represent the S.D. (N=4). For statistical analysis a 




Supplementary Figure 4. Human lung tissue infection experiments with Pan/99 (H3N2) 
and treatment with 10 nM endotoxin-free Qβ-phage capsids Qβ[Sia1]*. Error bars indicate 







2 Experimental Section 
2.1 NMR spectroscopy 
1H- and 13C-NMR spectra were recorded on a Bruker Avance 300 (300 MHz) and Avance 
600 (600 MHz) NMR spectrometer. Measurements were done at room temperature (rt), and 
chemical shifts are reported in parts per million (ppm) relative to the residual solvent peaks33. 
Coupling constants J are reported in Hz and multiplicities are given as s = singlet, br s = 
broad singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, and corresponding 
combinations of these. 
2.2 High resolution mass spectrometry of small molecules 
High resolution ESI-MS spectra were recorded on an Agilent 6220 TOF Accurate Mass 
coupled to an Agilent 1200 LC and were measured at 35°C between 100 – 2000 m/z. The 
used column was an Accucore RP-MS (30 x 2.11 mm; 2.66 µm particle size) ran with a flow 
of 0.8 mL/min and the following gradient (A = water, B = acetonitrile): 95% A + 5% B for 
0.2 min, then 95% A + 5% B to 1% A + 99% B until 1.1 min, then 1% A + 99% B until 2.5 
min. 
2.3 Material and reagents 
Column chromatography was performed with silica gel NORMASIL 60 (40–63 µm). For 
thin-layer chromatography (TLC) glass-backed silica gel plates (60 F254, 0.2 mm, Merck, 
Darmstadt, Germany) were used and detected either by UV or stained with anisaldehyde 
solution (112.5 mL methanol, 15 mL acetic acid, 7.5 mL H2SO4, 0.75 mL anisaldehyde) or 
potassium permanganate solution (1.5 g of KMnO4, 10 g K2CO3, 1.25 mL 10% NaOH, 
200 mL water).  
Acidic resin for ion-exchange (DOWEX®-50WX4) was washed extensively with methanol 
prior to use.  
Air and moist sensitive reactions were performed under an atmosphere of argon in flame-
dried Schlenk flasks. Dry solvents were obtained by Acros Organics. All other solvents and 
reagents were purchased from commercial suppliers as reagent grade and used without 
further purification. 
2.4 Syntheses of linkers and TEOTA ligand 
The linker compounds 2-azidoethanol (mEG-N3) 1
34, 2-[2-(2-azidoethoxy)ethoxy]ethanol 
(tEG-N3) 2
35, 2-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethanol (pEG-N3) 3
36 and 1-
azido-23-hydroxy-3,6,9,12,15,18,21-heptaoxatricosane (oEG-N3) 4
37, as well as the copper-
chelating ligand TEOTA38 were synthesized according to published protocols. 
2.5 Sialic acid donor synthesis 
Methyl ester 6 and peracetylated sialic acid 7 were synthesized according to a literature 
procedure by microwave assistance starting from commercially available N-
acetylneuraminic acid 539. The following steps towards fully protected thiosialoside donor 





Scheme S 1: Synthetic route towards oxazolidinione protected sialyl donor 10. Conditions: 
a) methanol. cat. trifluoroacetic acid, µwave, 80°C, 30 min; b) N,N-dimethylaminopyridine, 
pyridine, acetic anhydride, µwave, 70°C, 10 min; c) boron trifluoride etherate, 1-
adamantanethiol, dichloromethane, 0°C to room temperature, 1 d; d) 1.) methanesulfonic 
acid, methanol, 70°C, 1 d, 2.) 4-nitrophenyl chloroformate, sodium bicarbonate, 
water/acetonitrile 1:1, 0°C, 3 h; e) 1.) pyridine, acetic anhydride, room temperature, 14 h, 
2.) acetyl chloride, N,N-diisopropylethylamine, 0°C to room temperature, 2 h. 
 
Sialic acid chloride 11 was synthesized according a published protocol using peracetylated 
sialic acid 740: 
 
Scheme S 2: Synthesis of sialic acid chloride 11. Conditions: a) anhydrous methanol, 
hydrochloric acid, acetyl chloride, 0°C, 12 h. 
2.6 Syntheses of sialic acid azides 
Methyl [5-Acetamido-3,5-dideoxy-4,7,8,9-tetra-O-acetyl-2-azido-D-glycero-α-D-galacto-
non-2-ulopyranoside]onate (AcSia0-N3) was synthesized from sialic acid chloride 11 
according to a literature protocol41.  
The trisaccharides 2,3- and 2,6-sialyllactose azides were synthesized according to a 
previously published protocol42. The spectrometric data are in accordance with those given 
in the respective literature. 
2,3-Sialyllactose azide 2.3SL:  
ESI-HR-MS calculated for C23H38N4O18K
+: m/z = 697.1818, found: m/z = 697.1817. 
2,6-Sialyllactose azide 2.6SL:  
ESI-HR-MS calculated for C23H38N4O18H








2.7 General glycosylation method  
Glycosylations of the sialic acid donor with corresponding linker-azides were performed 
according to the literature protocol30. In a Schlenk flask powdered molecular sieves 4 Ǻ were 
evacuated, heated and flooded with argon three times. Subsequently, sialic acid donor 10 
(1.0 equiv.) and the corresponding linker 1 - 4 (1.5 equiv.) were added, evacuated for 15 min 
and then dissolved in dry CH2Cl2/MeCN (1:1, 0.05 mL per mg donor). The solution was 
stirred for 1 h at room temperature under argon and was then cooled down to –78 °C (dry 
ice/acetone bath) followed by the addition of N-iodosuccinimide (2.4 equiv.) and triflic acid 
(1.0 equiv.). The reaction was stirred for at least 1 h before it was quenched with 
triethylamine (1.5 equiv.) and then filtered through Celite® with CH2Cl2, washed with 20% 
aq. Na2S2O3 solution, dried over MgSO4 and at finally concentrated under reduced pressure. 
Purification was performed by column chromatography. 
2.8 General deprotection method  
Glycosylated azido sugars were dissolved in MeOH (0.05 mL per mg protected sugar). To 
the solution 1 M aqueous NaOH (0.015 mL per mg protected sugar) was added and stirred 
at room temperature for 30 min. Complete conversion was verified by TLC (EtOAc). The 
mixture was neutralized by the addition of DOWEX®-50WX4 H+ resin, filtered, 
concentrated under reduced pressure und finally lyophilized to provide the corresponding 
unprotected azido sugars. 
2.8.1 [5-Acetamido-3,5-dideoxy-2-azido-D-glycero-α-D-galacto-non-2-
ulopyranoside]onate (Sia0) 
Deprotection of AcSia0-N3 according to the general deprotection method led to Sia0-N3 as 
colorless solid (64.0 mg, 0.20 mmol, quant.). 
1H-NMR (300 MHz, D2O): δ = 1.65 (t, J = 12.0 Hz, 1H, 3-Hax), 1.98 (s, 3H, NAc), 2.61 (dd, 
J = 12.9, 4.1 Hz, 1H, 3-Heq), 3.50-3.66 (m, 3H), 3.75-3.88 (m, 4H). 
13C-NMR (75 MHz, D2O): δ = 21.9, 38.1, 51.4, 62.7, 67.3, 68.0, 70.6, 73.7, 89.4, 170.6, 
174.9. 
ESI-HR-MS calculated for C11H19N4O8
+: m/z = 335.1203; found: m/z = 335.1197. 
2.8.2 Methyl-((2-azido)ethyl-5-acetamido-7,8,9-tri-O-acetyl-5-N,4-O-carbonyl-3,5-
dideoxy-D-glycero-α-D-galacto-non-2-ulopyranoside)onate (AcSia1) 
By using linker 1 with the general glycosylation method, AcSia1-N3 was obtained after 
column chromatography (Hex/EtOAc 2:1 → 1:1) as light yellow oil (132 mg, 0.24 mmol, 
76%). 
1H-NMR (300 MHz, CDCl3): δ = 2.01-2.04 (m, 4H, OAc, 3-Hax), 2.12, 2.13 (2x s, 6H, 2x 
OAc), 2.48 (s, 3H, NAc), 2.87 (dd, J = 12.2, 3.5 Hz, 1H, 3-Heq), 3.36 (t, J = 4.8 Hz, 2H, 
CH2N3), 3.40-3.48 (m, 1H), 3.50-3.61 (m, 1H), 3.69-3.80 (m, 1H), 3.81 (s, 3H, COOMe), 
3.96-4.08 (m, 2H), 4.37 (dd, J = 12.3, 2.8 Hz, 1H), 4.61-4.68 (m, 1H), 5.39-5.48 (m, 1H), 
5.56-5.64 (m, 1H). 
13C-NMR (75 MHz, CDCl3): δ = 20.9, 21.2, 21.3, 24.8, 36.7, 50.6, 53.2, 59.1, 63.3, 64.9, 
68.9, 71.7, 74.9, 75.8, 99.1, 153.7, 168.8, 170.2, 170.3, 170.8, 172.1. 
ESI-HR-MS calculated for C21H29N4O13






ulopyranosidic acid (Sia1) 
Deprotection of AcSia1-N3 according to the general deprotection method led to Sia1-N3 as 
colorless gel (70.5 mg, 0.19 mmol, 85%). 
1H-NMR (300 MHz, D2O): δ = 1.76 (t, J = 12.1 Hz, 1H, 3-Hax), 2.00 (s, 3H, NAc), 2.70 (dd, 
J = 12.6, 4.4 Hz, 1H, 3-Heq), 3.46 (t, J = 4.9 Hz, 2H, CH2N3), 3.61-3.97 (m, 9H). 
13C-NMR (75 MHz, D2O): δ = 21.9, 39.2, 50.2, 51.6, 62.7, 63.0, 67.5, 68.1, 70.9, 72.7, 99.2, 
171.5, 174.9. 
ESI-HR-MS calculated for C13H21N4O9
-: m/z = 377.1314; found: m/z = 377.1302. 
2.8.4 Methyl-((2-(2-azidoethoxy)ethoxy)ethyl-5-acetamido-7,8,9-tri-O-acetyl-5-N,4-O-
carbonyl-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranoside)onate (AcSia3) 
By using linker 2 with the general glycosylation method, AcSia3-N3 was obtained after 
column chromatography (Hex/EtOAc 1:1 → 100% EtOAc) as light yellow oil (100 mg, 0.16 
mmol, 93%). 
1H-NMR (300 MHz, CDCl3): δ = 2.03 (s, 3H, Ac), 2.09-2.19 (m, 1H, 3-Hax) 2.13, 2.14 (2x 
s, 6H, OAc), 2.49 (s, 3H, NAc), 2.89 (dd, J = 12.1, 3.5 Hz, 1H, 3-Heq), 3.39 (t, J = 5.1 Hz, 
2H, CH2N3), 3.45-3.55 (m, 1H), 3.59-3.72 (m, 9H), 3.80 (s, 3H, COOCH3), 3.89-4.10 (m, 
3H), 4.37 (dd, J = 12.3, 2.8 Hz, 1H), 4.61 (dd, J = 9.3, 1.6 Hz, 1H), 5.37-5.46 (m, 1H), 5.57 
(dd, J = 8.0, 1.6 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ = 20.8, 21.0, 21.2, 24.7, 36.5, 50.7, 53.0, 59.0, 63.1, 65.1, 
69.1, 70.0, 70.2, 70.5, 70.7, 71.8, 75.0, 75.5, 99.3, 153.8, 168.7, 170.1, 170.3, 170.7, 172.1. 
ESI-HR-MS calculated for C25H36N4O15Na
+: m/z = 655.2069; found: m/z = 655.2048. 
2.8.5 (2-(2-(2-Azidoethoxy)ethoxy)ethyl)-5-acetamido-3,5-dideoxy-D-glycero-α-D-
galacto-non-2-ulopyranosidic acid (Sia3) 
Deprotection of AcSia1-N3 according to the general deprotection method led to Sia3-N3 as 
light yellow solid (71.0 mg, 0.15 mmol, 95%). 
1H-NMR (300 MHz, D2O): δ = 1.65 (t, J = 12.1 Hz, 1H, 3-Hax), 2.01 (s, 3H, NHAc), 2.71 
(dd, J = 12.5, 4.5 Hz, 1H, 3-Heq), 3.48 (t, J = 4.9 Hz, 2H, CH2N3), 3.53 – 3.60 (m, 2H), 3.63 
– 3.72 (m, 10H), 3.75-3.92 (m, 5H). 
13C-NMR (75 MHz, D2O): δ = 21.9, 39.3, 50.0, 51.6, 62.7, 63.2, 67.5, 68.1, 69.1, 69.29, 
69.32, 69.4, 70.9, 72.6, 99.1, 171.6, 174.8. 
ESI-HR-MS calculated for C17H29N4O11




By using linker 3 with the general glycosylation method, AcSia5-N3 was obtained after 
column chromatography (Hex/EtOAc 1:1 -→ 100% EtOAc) as light yellow oil (212 mg, 





1H-NMR (300 MHz, CDCl3): δ = 2.00-2.04 (m, 4H, OAc, 3-Hax), 2.12, 2.13 (2x s, 6H, 2x 
OAc), 2.48 (s, 3H, NAc), 2.88 (dd, J = 12.1, 3.5 Hz, 1H, 3-Heq), 3.38 (t, J = 5.0 Hz, 2H, 
CH2N3), 3.43-3.52 (m, 1H), 3.60-3.69 (m, 17H), 3.79 (s, 3H, COOMe), 3.87-4.07 (m, 3H), 
4.35 (dd, J = 12.3, 2.9 Hz, 1H), 4.59 (dd, J = 9.3, 1.6 Hz, 1H), 5.35-5.45 (m, 1H), 5.56 (dd, 
J = 8.0, 1.6 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ = 20.9, 21.1, 21.3, 24.8, 36.6, 50.8, 53.1, 59.1, 63.2, 65.2, 
69.1, 70.1, 70.2, 70.59, 70.64, 70.68, 70.73, 70.77, 70.8, 71.9, 75.1, 75.6, 99.4, 153.8, 168.8, 
170.2, 170.3, 170.8, 172.1. 
ESI-HR-MS calculated for C29H44N4O17Na
+: m/z = 743.2594; found: m/z = 743.2546. 
2.8.7 (2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethyl)-5-acetamido-3,5-dideoxy-
D-glycero-α-D-galacto-non-2-ulopyranosidic acid (Sia5) 
Deprotection of AcSia5-N3 according to the general deprotection method led to Sia5-N3 as 
yellow oil (123 mg, 0.22 mmol, 79%). 
1H-NMR (300 MHz, D2O): δ = 1.75 (t, J = 12.1 Hz, 1H, 3-Hax), 2.00 (s, 3H, NAc), 2.69 (dd, 
J = 12.7, 4.4 Hz, 1H, 3-Heq), 3.48 (t, J = 4.9 Hz, 2H, CH2N3), 3.56-3.76 (m, 20H), 3.77-3.88 
(m, 4H), 3.88-3.97 (m, 1H). 
13C-NMR (75 MHz, D2O): δ = 21.9, 39.3, 50.0, 51.6, 62.7, 63.1, 67.4, 68.1, 69.1, 69.3, 
69.38, 69.4, 69.5, 70.9, 71.6, 72.6, 99.1, 171.6, 174.8. 
ESI-HR-MS calculated for C21H37N4O13





By using linker 4 with the general glycosylation method, AcSia8-N3 was obtained after 
preparative HPLC (C18, H2O/MeCN 95:5 → 10:90 in 60 min) and lyophilization as yellow 
thick oil (74.2 mg, 87.0 µmol, 58%). 
1H-NMR (300 MHz, CDCl3): δ = 1.87 (s, 3H), 1.97 (t, J = 12.7 Hz, 1H), 2.02, 2.03, 2.13, 
2.14 (4 x s, 3H each), 2.60 (dd, J = 12.8, 4.6 Hz, 1H), 3.38 (t, J = 5.1 Hz, 2H), 3.41-3.49 (m, 
1H), 3.58-3.70 (bm, 28H), 3.79 (s, 3H), 3.84-3.93 (m, 1H), 4.01-4.13 (m, 3H), 4.28 (dd, J = 
12.4, 2.6 , Hz, 1H), 4.77-4.91 (m, 1H), 5.09-5.20 (m, 1H), 5.27-5.34 (m, 1H), 5.34-5.42 (m, 
1H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 20.8, 20.89, 20.92, 21.2, 23.2, 38.0, 49.4, 50.7, 52.8, 62.4, 
64.5, 67.3, 68.6, 69.2, 70.06, 70.1, 70.5, 70.57, 70.59, 70.60, 70.65, 70.69, 70.72, 72.5, 98.8, 
168.3, 170.1, 170.2, 170.3, 170.7, 171.1 ppm. 
ESI-HR-MS calculated for C36H60N4O20H
+: m/z = 869.3874, found: m/z = 869.3870. 
 
2.8.9 (2-(2-(2-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)-
ethyl)-5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranosidic acid (Sia8) 
Deprotection of AcSia8-N3 according to the general deprotection method led to Sia8-N3 as 





1H-NMR (300 MHz, CDCl3): δ = 1.65 (t, J = 12.1 Hz, 1H, 3-Hax), 2.01 (s, 3H, NAc), 2.72 
(dd, J = 12.4, 4.5 Hz, 1H, 3-Heq), 3.48 (t, J =4.8 Hz, 2H, CH2N3), 3.52-3.60 (m, 3H), 3.63-
3.79 (m, 30H), 3.79-3.94 (m, 4H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 21.9, 40.1, 50.0, 51.7, 62.5, 63.1, 68.1, 69.1, 69.3, 69.37, 
69.42, 71.6, 72.4, 100.4, 173.3, 174.9 ppm. 
ESI-HR-MS calculated for C27H50N4O16Na
+: m/z = 709.3120, found: m/z = 709.3116. 
2.9 Synthesis of GalNAc azide Gal3 
Peracetylated galactosamine 1343, oxazoline 1444 and protected GalNAc azide AcGal345 
were synthesized according to literature protocols starting from commercially available 
galactosamine hydrochloride 12: 
 
Scheme S 3: Synthetic route towards galactose derivative Gal33. Conditions: a) pyridine, 
acetic anhydride, 0°C to room temperature, 18 h; b) trimethylsilyl 
trifluoromethanesulfonate, 1,2-dichloroethane, 50°C, 17 h; c) trimethylsilyl 
trifluoromethanesulfonate, 1,2-dichloroethane, 4Å molecular sieves, room temperature, 
12 h; d) 1 M sodium hydroxide, methanol, room temperature, 30 min. 
2.9.1 2-[2-(2-azidoethoxy)ethoxy]ethoxy-2-N-acetylamido-2-deoxy-β-D-
galacto-pyranoside Gal3 
Deprotection of AcGal3-N3 according to the general deprotection method led to Gal3-N3 as 
pale yellow gel (515 mg, 1.36 mmol, quant.). 
1H-NMR (300 MHz, D2O): δ = 2.02 (s, 3H, NHAc), 3.48 (t, J = 5.1 Hz, 2H, CH2N3), 3.62-
3.79 (m, 13H), 3.83- 3.93 (m, 2H), 3.95-4.04 (m, 1H), 4.48 (d, J = 8.4 Hz, 1H, 1-H). 
13C-NMR (75 MHz, D2O): δ = 22.1, 50.0, 52.2, 60.8, 67.7, 68.7, 69.1, 69.4, 69.5, 69.6, 71.0, 
75.0, 101.4, 174.6. 
ESI-HR-MS calculated for C14H26N4O8Na
+: m/z = 401.1648; found: m/z = 401.1649. 
2.10 Generation of E. coli B834(pQE60_Qβ(K16M), pREP4) 
E. coli B834 (DE3) was chosen as expression host for the Qβ(K16M) mutant as previously 
reported by the Davis lab25. Electrocompetent host cells were double-transformed with the 
circular nucleic acids pQE60_Qβ(K16M) and pREP4 (kindly provided by A. K. Udit, 
Occidental College, LA, CA)29 carrying the antibiotic resistance cassettes ampicillin and 





a pulse of 1.8 kV. Transformed cells were cured in Luria-Bertani (LB) medium at 37 °C and 
subsequently incubated on LB-agar plates at 37 °C overnight. 
2.11 Recombinant Qβ(K16HPG) expression and purification 
New minimal media (NMM) was used to cultivate and express Qβ(K16M) virus like 
particles at all times.  
A preculture of E. coli B834(pQE60_Qβ(K16M), pREP4) was prepared in 5 mL NMM 
supplemented with kanamycin (50 mg/L) and ampicillin (100 mg/L), which was 
subsequently incubated at 37 °C, 200 rpm for 8 h. 1-2 L NMM substituted with kanamycin 
(50 mg/L), ampicillin (100 mg/L) and L-methionine (130 mM) were inoculated with 6 mL 
of preculture. The resulting main culture was incubated at 30 °C, 180 rpm overnight (18 h). 
Subsequently, the culture was washed twice with NMM supplemented with kanamycin 
(50 mg/L) and ampicillin (100 mg/L) lacking L-methionine (400 rpm, 4 °C, 20 min)) twice. 
Washed culture pellets were resuspended in minimal media supplemented with kanamycin 
(50 mg/L), ampicillin (100 mg/L), and the resulting suspension was brought to half the 
cultivation volume in preheated NMM supplemented with kanamycin (50 mg/L), ampicillin 
(100 mg/L) at 30 °C. The ncAA HPG (L-homopropargylglycine) was added to the culture 
(50 mg/L). The expression culture was incubated at 37 °C, 180 rpm for 30 min. 
Subsequently, the culture was incubated at 30 °C, 180 rpm for 1 h. Expression of Qβ(K16M) 
was induced with IPTG (1 mM) followed by an incubation at 30 °C, 180 rpm, overnight 
(18 h). Cells were harvested (8,000 x g, 4 °C, 20 min) and stored at -20 °C until purification. 
Cell pellets were thawed and resuspended in lysis buffer (100 mM potassium phosphate, pH 
7.3) and lysed by ten passes through an LM10 microfluidizer (Microfluidics, Westwood, 
Massachusetts) at 14,000 psi. The resulting slurry was incubated with DNaseI in the 
presence of 10 mM MgCl2 at room temperature for 30 min, and subsequently centrifuged to 
remove cell debris (50,000 x g, 20 min, 4 °C). To the supernatant 10% (w/v) PEG8000 and 
NaCl (100 mM final concentration) was added, and incubated overnight at 4 °C. The 
precipitate was collected by centrifugation (10,000 rpm, 15 min, 4 °C) and dissolved in 
100 mM potassium phosphate buffer (pH 7.3). Extraction with CHCl3/nBuOH (1:1) was 
carried out and phase separation as well as removal of insoluble material was achieved by 
centrifugation (10,000 rpm, 15 min, 4 °C). The resulting Qβ[Hpg] capsid containing 
supernatant was stored at 4 °C. Further purification was achieved by sucrose gradient (10-
40% (w/v)) ultracentrifugation in an Optima LE-80K ultracentrifuge (Beckman Coulter) 
with an SW 40 Ti rotor (125,000 x g, 4.5 h, 4 °C). Qβ[Hpg] containing fractions were 
identified by SDS-PAGE, pooled, concentrated and washed in 30 kDa cut-off centrifugal 
filter units. 
2.12 Determination of Qβ VLP concentration 
Concentrations of Qβ containing solutions were measured by commercially an available 
Pierce™ BCA Protein Assay Kit (catalogue number 23225) using a BSA standard for 
calibration. Evaluation of the assay results were carried out by using the software 
Mathematica (Wolfram Research, Inc., Version 10.2, Champaign, IL).  
2.13 ESI mass analysis of Qβ coat protein 
Reaction progress and final products of conjugation reactions were analyzed by LC-ESI-
MS. For that, 8 µL of capsid solution (23 – 177 µM of protein) were treated with 2 µL of 





Corporation) equipped with a Waters Acquity UPLC Protein BEH C4 300 Å column using 
water (A) and acetonitrile (B) as eluent which both contained 0.1% formic acid (95% A 
isocratic for 2.5 min, then gradient to 100% B in 7.5 min). The UPLC was coupled to an 
LCT Premier Micromass Technologies spectrometer operated at 3.2 kV capillary voltage, 
60 V cone voltage, 300 °C desolvation temperature, 150 °C source temperature and 600 L/h 
desolvation gas. The obtained data were processed by MassLynx software (4.1, Waters 
Corporation) and protein spectra were deconvoluted by Waters MaxEnt1 algorithm. 
Myoglobin was used as reference for spectra calibration. 
2.14 Tryptic digest – ESI orbitrap 
Enzymatic in-gel digestions of Qβ conjugates were performed following a standard 
protocol46. Follow-up analysis was carried out on an Orbitrap Fusion (Thermo Scientific) 
connected to a Dionex Ultimate 3000 NCS-3500RS Nano LC system. Each sample was 
loaded for 5 min at a flow rate of 5.6 µL/min (2% acetonitrile, 0.05% trifluoroacetic acid) 
onto an Acclaim PepMap 100 C18 (3 µm, 75 µm  20 mm) pre-column, followed by gradient 
elution (10% acetonitrile, 0.1% formic acid for 7.8 min, 18% acetonitrile in 1 min, followed 
by 30% acetonitrile in 20 min and 50% acetonitrile for another 5 min, then 80% acetonitrile 
in 4 min, flow = 200 nl/min) on a PikoTip column (75 µm  250 mm) equipped with 
ReproSil-Pur 120 C18-AQ 3 µm material. Mass spectra were obtained in a range of 350–
1500 m/z with a resolution of 12000. Subsequent MS/MS data were obtained by electron-
transfer dissociation to detect intact carbohydrate modifications. 
2.15 Bioconjugation 
Conjugation reactions were performed following a published protocol25. In the following, a 
typical conjugation procedure is described. To 500 µL of a 1.2 µM Qβ[Hpg] capsid solution 
(213.5 µM coat protein ≙ Hpg concentration) were added 90 eq. of the respective azido 
sugar, dissolved in 250 µL of 100 mM potassium phosphate buffer. Stock solutions of CuBr 
(99.999% trace metal basis, 10 mg/mL) and TEOTA (100 mg/mL) in acetonitrile were 
prepared. Subsequently, 187.6 µL of the CuBr solution and 72.6 µL of the TEOTA solution 
were mixed and 200 µL of the resulting Cu/ligand mix were transferred to the protein/sugar 
mixture. Reaction proceeded at 25°C at 800 rpm on a thermoshaker for 30 min. Another 
100 µL portion of the Cu/ligand mix were added to the reaction and after additional 1.5 h 
the precipitate was removed by centrifugation and large excess of low molecular weight 
compounds was reduced by spin filtration. Purification of the reaction crude was again 
achieved by sucrose gradient ultracentrifugation (125,000 x g, 4.5 h, 4°C in a SW40 Ti rotor, 
10-40% gradient). The relevant fractions were identified by SDS-PAGE, pooled, 
concentrated and washed in 30 kDa cut-off centrifugal filter units. Further polishing steps 
included dialysis against EDTA-containing potassium phosphate buffer (5 mM EDTA) and 
SEC on an Äkta FPLC system equipped with a Superose6 column. 
The synthesized conjugates were characterized by intact protein ESI-MS to confirm 
successful conjugation and determine With our experimental set up, we cannot completely 
rule out the presence of Met traces in samples.47 This incorporation originates from Met 
metabolic turnover in bacterial hosts as well as partial presence at the N-terminus due to 
incomplete cleavage by aminopeptidases as reported in other systems.48 If the N-terminal 
Met was replaced by Hpg a second conjugation can occur, which we observed as minor side 





the correct position of the modification. Residual copper content after copper-catalyzed 
bioconjugation reaction was determined exemplary for Qβ[HPG] and Qβ[Sia1] by ICP-MS 
measurements (Table S 1). The copper content was increased more than 20-fold after the 
reaction (Entry 1 vs. Entry 2), if no dialysis against EDTA buffer was performed. After 
dialysis, copper levels were reduced to initial levels and below (Entry 3, three samples 
measured).  
Table S 1: ICP-MS measurements of the copper content in Qβ samples before CuAAC, after 
CuAAC without dialysis and after CuAAC with dialysis as purification step. 
Entry Sample Copper content in a 100 nM capsid sample 








< 0.5 µM 
 
2.16 Cryo-electron microscopy 
For binding experiments 15 µl of Qβ phage capsids (concentration 200 nmol/L) were 
incubated with 15 µL of influenza virus A/X 31 (~1 mg/mL total protein) with gentle 
agitation for 30 min at room temperature. Perforated (1 µm hole diameter) carbon film-
covered microscopical 200 mesh grids (R1/4 batch of Quantifoil, MicroTools GmbH, Jena, 
Germany) were hydrophilized by 60 s glow discharging at 8 W in a BALTEC MED 020 
device (Leica Microsystems, Wetzlar, Germany). Then 5 µL of the corresponding sample 
were pipetted to the hydrophilized grid and the supernatant fluid was immediately removed 
with a piece of filter paper until an ultrathin layer of the sample solution (typical thickness 
of 100-250 nm) was obtained spanning the holes of the carbon film. The sample was 
instantly vitrified by plunging the grids into liquid ethane using a guillotine-like apparatus. 
The vitrified sample was subsequently transferred under liquid nitrogen into a Tecnai F20 
TEM (ThermoFisher Scientific Inc., Waltham (MA), USA) equipped with a field emission 
gun operating at 160 kV by the use of a Gatan tomography cryo-holder (Model 914). 
Microscopy was carried out at a 94 K sample temperature using the low-dose protocol of the 
microscope. Micrographs were taken with a FEI Eagle 4k × 4k CCD camera using the 
twofold binning mode. To generate stereo images, the same image section was recorded at 
two different tilt angles (4° and -4°) using the Compustage of the microscope. The resulting 
micrographs were aligned using the software StereoPhoto Maker (Masuji Suto, Japan). 
2.17 Cryo-electron tomography   
Tomograms were acquired on a Titan Krios™ transmission electron microscope 
(ThermoFisher Scientific Inc., Waltham (MA), USA) operating at 200 kV and equipped with 
a Volta phase plate. Single axis tilt series (±64° in 2° tilt angle increments) were recorded 
with a Falcon-II 4k × 4k direct electron detector at full resolution (29 K primary 
magnification) with a total dose less than 70 e-/Å2. Tomogram reconstruction was done using 
ThermoFisher Inspect3D software. Manual segmentation and 3D rendering were performed 





3 Biophysical and biological methods 
3.1 Cell culture 
The cell lines MDCK-II (Madin-Darby canine kidney epithelial) (ATCC, Germany), and 
A549 (Human lung adenocarcinoma epithelial) (CLS, Germany) were maintained in 
DMEM (supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37 °C and 5% CO2. 
3.2 Influenza virus strains  
Influenza A/X31 virus (H3N2; HA and NA genes derived from A/Aichi/2/68, reassorted 
with internal segments of A/Puerto Rico/8/1934 (H1N1)), A/mallard/Germany/439/2004 
(H3N2), A/Puerto Rico/8/1934 (H1N1), A/WSN/1933 (H1N1) or A/Teal/Germany/2005 
(H5N1; HA and NA genes derived from A/Teal/Germany/2005, reasserted with internal 
segments of A/WSN/1933 (H1N1), kindly provided by Dr. Mair, Molecular Biophysics, HU 
Berlin) were harvested from allantoic fluid of embryonated chicken eggs. 
A/Panama/2007/1999 (H3N2) was propagated in MDCK-II cells, and the Influenza 
B/Thüringen/2/2006 patient isolate was propagated on Vero E6 cells. Harvested stock virus 
was clarified upon low speed centrifugation (300 x g, 10 min) and stored as aliquots at -
80 °C. Viral titers were assessed by standard plaque assay titrations on MDCK-II cells. 
3.3 Microscale thermophoresis 
Measurements were performed using a Monolith NT.115 instrument (Nanotemper), and 
standard glass capillaries (Nanotemper) at 22 °C. Each inhibitor was twofold serially diluted 
and mixed with equal amounts of R18 labeled X31 (4 HAU, cfinal≈0.1 nM virus particles). 
After a short incubation, the inhibitor-virus mix was loaded in glass capillaries and measured 
for initial fluorescence and change in fluorescence upon a thermophoresis measurement 
(MST power: 80%, green LED power 100%). For analysis, the T-jump with 5 s 
thermophoresis was used and gated as shown in the supplementary analytical data. In order 
to determine the noise level, triplicates of the same virus dilution were measured leading to 
ΔFvirus≈ 6 FU. The change in fluorescence was expressed as fraction bound of the maximum 
fluorescence in the bound state. Apparent dissociation constants were deduced from a 
binding saturation fit of mean values of independent experiments. The function for fitting is 




(𝐵 + 𝐿 + 𝐾𝑑𝑎𝑝𝑝 − √(𝐵 + 𝐿 + 𝐾𝑑𝑎𝑝𝑝)
2
− 4𝐵 ∗ 𝐿
2
 ) 
with L being the ligand concentration at each data point, B being the constant concentration 
of the fluorescent molecule, F being the fraction of the complex between B and L to the total 
amount of binding sites (B) at each data point. 
3.4 Hemagglutination inhibition assay 
Different virus strains were incubated with human or chicken erythrocytes, respectively, to 
yield agglutination (in the absence of an inhibitor) and concentration-dependent inhibition 
of agglutination (in the presence of an inhibitor). Inhibitors were twofold serially diluted in 
Dulbecco’s phosphate buffered saline (DPBS). Then, four hemagglutination units (HAU) 
containing 4∙107 virus particles were added to all wells. Viral particle concentration was 
estimated as described by Desselberger et al.49. After 30 min incubation at room temperature 
(rt), 50 µl of a 1% erythrocyte solution (~2∙106 cells µl-1) was added, gently mixed and 
incubated for 60 min at rt. For human pathogenic strains human erythrocytes (α-2,6’-





used. The inhibitor constant Ki(HAI) reflects the lowest inhibitor concentration, which is 
necessary to achieve complete inhibition of hemagglutination caused by the influenza virus. 
To check for full hemagglutination inhibition, the microtiter plate was tilted by 60° to cause 
droplet formation from the red blood cell pellet50. 
3.5 Cytotoxicity and cytopathic effect inhibition assay 
Viral infection inhibition and cytotoxicity were monitored using a Cell Titer Glo (Promega) 
assay according to the standard protocol of the manufacturer. The provided reagents detect 
the overall ATP level of cells via luciferase. The ATP level being proportional to the number 
of viable cells was recorded upon luminescence detection with a plate reader (Spark, Tecan). 
Cells infected with Influenza A virus cause a cytopathic effect, which goes along with 
reduced number of cells or cell viability, respectively.  
Here, 4,000 A549 cells were seeded one day before infection in a white 384 well plate. On 
the next day, A/X31 was pretreated with Qβ phages in a twofold dilution series for 30 min 
at rt under slight agitation. Then, the inhibitor-virus (MOI 0.05) mix was transferred to cells, 
following incubation for 24 h at 37 °C. Cytotoxicity was assessed adding inhibitor without 
virus to cells. Following, 25 µl Cell Titer Glo solution was added to each well and incubated 
for 10 min at rt. Finally, luminescence was measured, and data were normalized to maximum 
viral cytopathogenicity as follows: 




Dose response curves of mean values (n≥3) were fitted using a four parametric logistic fit to 
obtain IC50 values. The asymmetric standard error (SE) of the fit is given as logIC50 . 
3.6 Infection inhibition assay 
A/Panama/2007/1999 (H3N2) virus was pretreated in an inhibitor titration experiment with 
Qβ[Sia1] and maintained for 30 min at rt. The day before, 5x104 A549 cells were seeded in 
an 8-well plate (ibidi). On the following day, the cells were washed once with DPBS++ and 
infected with inhibitor or DPBS treated A/X31 (MOI 1) for 1 h on ice to synchronize the 
infection. Unbound virus was removed by aspiration of the supernatant, and subsequent 
washing with infection media (DMEM, 1% FCS). Following that, cells were incubated for 
6 h at 37°C and analyzed for viral nucleoprotein expression by immunostaining as follows:  
Cells were washed, fixed with 4% paraformaldehyde and permeabilized with 0.5% (w/v) 
triton X-100. Furthermore, the cells were blocked with blocking buffer (DPBS++, 
supplemented with 3% BSA and 100 mM L-glycine) for 2 h at rt. Immunostaining was 
performed with a FITC-coupled mouse α-NP monoclonal antibody (preference for nuclear 
NP, Millipore, 1:500 in DPBS++ with 1 % BSA), and a primary unlabeled mouse α-NP 
monoclonal (Millipore, 1:500 in DPBS++ with 1 % BSA). The unlabeled antibody was 
detected using an Alexa488 labeled secondary goat α-mouse polyclonal antibody (preference 
for cytoplasmic NP; ThermoFisher Scientific; 1:1000 in DPBS++ with 1 % BSA). Cellular 
DNA was stained using DAPI. Confocal microscopy was assessed using an Olympus FV 
1000 microscope. Acquired images were analyzed for viral NP expression using an ImageJ 
software as follows: Cells were automatically identified by an ImageJ script from the DAPI 
signal of the stained nuclei. Each object, representing one cell, was further analyzed for the 
fluorescence intensity coming from the FITC coupled α-NP monoclonal antibody. Median 





infected, DPBS-treated cells. Statistics were performed using a one-way ANOVA analysis 
with a Dunnett's multiple comparison test to the infected, DPBS treated control. 
 
3.7 Inhibition of viral propagation in cell culture 
MDCK-II cells were infected with IAV A/X31 or A/Panama/2007/1999 with a MOI of 0.01 
for 45 min. Unbound virus was washed off, followed by incubation in infection medium 
(MEM supplemented with 1mM glutamine, 0.2 % bovine serum albumin, 1 mg/ml TPCK-
trypsin and 1% penicillin/streptomycin) containing different concentrations of Qβ capsid 
[Sia1]. After 24 h virus titers in the supernatant were determined by plaque titration on 
MDCK-II cells. Results are given as plaque forming units per ml (PFU/ml). Values were 
log-transformed and normalized for IC50 calculation with GraphPad Prism 7. 
 
3.8 In vivo infection inhibition study 
Animals were maintained and handled according to the Directive 86/609/EEC of the 
European Community Council and to the institutional, state and federal guidelines. All 
animal protocols were approved by the ethics committee of the Landesamt für Gesundheit 
und Soziales (LAGeSo, Berlin, Germany) with registration number G0011-15. Animals 
were housed under standard conditions of 12 h light/dark cycle and given access to food and 
water ad libitum. Experiments were performed with 8 weeks old BALB/c mice (Charles 
River) as previously described51. First, mice were sedated by an intraperitoneal injection of 
200 µl Cepetor (4 µg/100 µl) and anesthetized by isofluran inhalation. Then, A/X31 virus 
was preincubated with inhibitor for 30 minutes at rt in DPBS++ before the 25 µl virus-
inhibitor mix was distributed to both nostrils of the mice. After complete uptake of the virus-
inhibitor solution, mice were revitalized, by injecting 200 µl antisedan (2 µg/100 µl) 
intraperitoneally. Groups of five mice were maintained per cage and experiment for 10 days. 
The mice were weighed daily and the influenza virus infection related loss in body weight 
was expressed as percentage of the initial body weight. As soon as animals reached a 
maximum score of 3 for signs of discomfort and suffering or if a loss in body weight of more 
than 20 % was observed, according to the regulations, mice were sacrificed upon cervical 
dislocation. At the end of the experiment (day 10), all mice were sacrificed upon cervical 
dislocation. 
Data were statistically analyzed by comparison of infected, inhibitor treated mice to infected, 
DPBS treated animals, conducting a one-way ANOVA and Dunnett’s multiple comparison 
test.  
3.9 Ex vivo infection of human lung tissue 
Tumor-free normal human lung tissue was cut into small pieces (weight approx. 0.1 – 0.2 mg 
per piece) and incubated in RPMI 1640 medium overnight to wash off clinically applied 
antibiotics. The study was approved by the ethics committee at the Charité clinic (projects 
EA2/050/08 and EA2/023/07) and written informed consent was obtained from all patients. 
The infection experiments were done in RPMI 1640 infection medium (supplemented with 
0.3 % bovine serum albumin and 2 mM L-glutamine) at 37 °C with 5 % CO2 as described 
previously52-54. For replication analyses, human lung tissue explants were inoculated with 2 
× 105 PFU in RPMI 1640 medium for 1.5 h at room temperature. Excess virus was removed 
by washing with phosphate-buffered saline (DPBS) and lung tissue was incubated for 48 hpi 
(hours post infection) in RPMI infection medium containing 10 nM of Qβ[Sia1] inhibitor. 
At 24 hpi, an additional 10 nM of Qβ[Sia1] inhibitor was added to the corresponding well to 





tissue specimens from four donors. For replication analysis, at 0, 16, 24 and 48 hpi 
supernatants of infected lung tissue were harvested and viral titers were determined by 
standard plaque titration assay. 
3.10 Analysis of proinflammatory and antiviral cytokines 
The immunogenicity of Qβ phage capsids was studied in comparison to capsids which 
underwent additional purification to remove residual LPS. Here, an aqueous two-phase 
separation (ATPS) protocol was adapted from Branston and colleagues55, and conducted as 
follows: To a 500 nM capsid solution in 100 mM KPi-buffer, pH = 7.4, 1 % (v/v) Triton X-
114 was added at 4 °C, mixed and incubated for 5 min at 4 °C. In the meantime, Bio-Beads 
SM-2 (Bio-Rad) were soaked in KPi buffer for 5 min. The sample was warmed to 37 °C, 
incubated at this temperature for another 5 min and centrifuged at 37 °C for 1 min at 15.000 
x g. The soaking buffer from the BioBeads was mostly discarded and the upper, detergent-
poor fraction from the sample was transferred to the Bio-Bead suspension. Following, 2 h 
incubation at rt with gentle inversion the Bio-Beads were removed upon filtration through a 
0.45 µm syringe filter. Aliquots for determination of endotoxin content were subsequently 
frozen at -80 °C until the day of the experiment. 
Endotoxin concentration was determined by rFC-assay (PyroGene™ Recombinant Factor C 
Endotoxin Detection Assay, Lonza). Samples were diluted 1:100 in endotoxin-free water for 
the assay. The diluted samples showed responses at the assay's lower detection limit, 
corresponding to endotoxin concentrations of < 1 EU/mL in the non-diluted samples (n = 4). 
The spike recovery under the employed assay conditions was 86±15%, n = 4. (Spike 
recovery is a parameter for validity of results, allowed range is 50-200%). 
Cytokine release was measured from supernatants 48 h after lung tissue treatment using 
ELISA Ready-SET-Go! kits (ThermoFisher) for TNF-α and IL-1β, and a human IFN-β 
ELISA Kit from PBL Assay Science. Measurements were conducted according to the 








4 Supplementary Notes 
Sia duplets and triplets: 
A Qβ capsid has a diameter of approximately 25 nm. It consists of 90 protein dimers that 
form a truncated icosahedron. Therefore, the anchoring points of the Sia units are placed 
along the edges of hexagonal or pentagonal substructures (Supplementary Figure 2a). 
Thereby, two thirds of all edges connect a hexagon-hexagon substructure and one third 
connect hexagon-pentagon substructures. 
The distance between neighboring Sia units depends on whether these units are found along 
the edge of a hexagonal or pentagonal substructure. In Supplementary Figure 2b Sia 
triplets within neighboring hexagonal-pentagonal substructures are shown, whereas 
Supplementary Figure 2c shows Sia triplets within two neighboring hexagonal 
substructures. Similarly, Supplementary Figure 2d-f shows Sia duplets within neighboring 
hexagonal-pentagonal substructures (Supplementary Figure 2d and e) or two neighboring 
hexagonal substructures (Supplementary Figure 2f). 
The distance between Sia duplets (indicated by dashed lines in Supplementary Figure 2d-
f) varies between 3.2 nm and 7.2 nm, whereas Sia triplets (Supplementary Figure 2b and 
c) exhibit an edge length of d1=5.0 nm (dashed line), d2=5.9 nm (solid line) or d3=6.2 nm 
(dotted line).  
As we will show further below, the binding of the Qβ capsid towards HA is dominated by 
the two smallest Sia triplets. 
Dissociation constant: 




,      (1) 
with [L] the concentration of free ligands, i.e. the concentration of unbound Qβ capsid, [R] 
the concentration of free receptors, here the HA-trimers, and [LR] the concentration of bound 
ligand-receptor pairs. For dilute concentrations interaction between ligands as well as 
interactions between receptors can be neglected and the dissociation constant follows from 




,      (2) 
with 𝑞X the partition function of species 𝑋 and 𝑉 the volume of the system.  
In the following we derive the partition function of free and bound ligands and receptors, 
from which we deduce an expression for the dissociation constant. 





𝑞SiaΩSia∫𝑉𝑑𝐫𝑗𝑃str(𝐫𝑗, 𝑛),      (3) 
with 𝑉 the volume of the entire system, 8𝜋2 accounts for the angular space of a rigid body, 
which is the product of the area of a unit sphere 4𝜋, times a factor 2𝜋 for rotations around 
the body axis. The partition function over the internal degrees of freedom of the Qβ capsid 
is denoted as 𝑞Q𝛽, while the partition function over the internal degrees of freedom of a single 





their EG linkers. The probability to stretch the j-th EG linker, consisting of 𝑛 monomers, 
along the end-to-end vector 𝐫j is described by 𝑃str(𝐫j, 𝑛). We determined 𝑃str from molecular 
dynamics simulation, as described in detail further below. The angular space of the Sia unit 
is denoted as ΩSia. Steric repulsions between Sia and the linker significantly restrict the 
degrees of freedom of Sia (schematically indicated in Fehler! Verweisquelle konnte nicht 
gefunden werden.Fehler! Verweisquelle konnte nicht gefunden werden.Supplementary 
Figure 2g). Hence, the angular space of each Sia unit is smaller than the angular space of a 
free rigid body (8𝜋2). To quantify the restriction of angular degrees of freedom, we define 
the angular restriction factor 𝜔Sia = ΩSia/8𝜋
2. From a fit to the experimental data (Fig. 3c in 
the main text) we determine a value of 𝜔Sia=0.05. For comparison, in the limiting case 
without any steric exclusion, the angles 𝜙 and 𝜓 are limited by 2𝜋, whereas 𝜃 is limited by 
𝜋, which leads to 𝜔𝑆𝑖𝑎=1.0. In a previous study an angular restriction factor of 𝜔𝑆𝑖𝑎=0.03 was 
found for inhibitors against the pentavalent cholera toxin and the heptavalent anthrax 
receptor56. The slightly larger value of 𝜔𝑆𝑖𝑎=0.05 that we obtained for the Qβ capsid in the 
present work might arise due to the different linker and ligand chemistries as well as due to 
the fact that the angular restriction factor also accounts for interactions between the linker 
and the HA surface. 
To simplify the partition function 𝑞L of the free ligand (Eq.3) we impose that the stretching 
probability is normalized by ∫ 𝑑r𝑗𝑃𝑠𝑡𝑟(r𝑗, 𝑛) = 1𝑉
. Hence, 𝑞L becomes: 
𝑞L = 𝑉8𝜋
2𝑞Q𝛽(𝑞SiaΩSia)
180      (4) 
For free monovalent Sia the partition function of the Qβ capsid as well as the restricted 
angular space ΩSia in Eq.4 are omitted and the partition function reads: 
𝑞L
mono = 𝑉8𝜋2𝑞Sia      (5) 






      (6) 
in which the 𝑖-th binding mode represents 𝑖 = 1,2,3 bound Sia units.  
The partition function of the 𝑖-th binding mode factorizes into the contribution from the 
receptor 𝑞R and contributions from the bound ligand: 
𝑞LR
(𝑖)
= 𝑞R𝑁(𝑖)𝑞Q𝛽∫ 𝑑𝐫Q𝛽∫ 𝑑𝝎Q𝛽 ∏
𝑗=1
180
























𝑁(𝑖) in Eq.7 is a permutation factor, with 𝑁(𝑖)=180/𝑖. In case of monovalent binding 𝑁(1) =
180, which reflects the number of Sia units and hence the number of binding permutations 
per capsid. For divalent binding of a certain Sia duplet, there are 90 equivalent Sia duplets 
(𝑁(2) = 90). All equivalent Sia duplets are obtained by rotation around the capsid axes. 
Similarly, considering the capsid structure and rotating a certain Sia triplet around the capsid 
axes, leads to 60 equivalent Sia triplets, hence 𝑁(3) = 60.  





 denote the sums over all monomers, duplets 
(indicated as dashed lines in Supplementary Figure 2d-f) or triplets (indicated as red 





and a pentagonal substructure. The prefactors 2/3 and 1/3 account for the ratio of hexagonal 
and pentagonal substructures. ∑
{𝑘}
 is the sum over all permutations by which 𝑖 Sia units can 
bind to the three receptor binding pockets for a given capsid position and capsid orientation. 
Different permutations between the three HA binding pockets and the 𝑖 Sia units result in 
different linker stretching and hence influence 𝑃str.  
The position and orientation of the Qβ capsid relative to the receptor is denoted as 𝐫Q𝛽 and 
𝝎Q𝛽 (schematically shown in Supplementary Figure 2h), where 𝝎Q𝛽 = (𝜙, 𝜃, 𝜓) 
summarizes the Euler angles by which the capsid can rotate. The volume of the receptor 
binding pockets and the angular space of Sia inside the binding pockets are described by 𝑉bp 
and Ωbp, respectively. Each bound Sia gains the binding free energy Δ𝐺, whereby 𝛽 denotes 
the inverse thermal energy.  
For a bound monovalent Sia unit, we omit all terms in Eq.7 associated with the linkers and 
the capsid. Hence, 𝑞LR simplifies to: 
𝑞LR
mono = 𝑞R𝑞SiaΩbp𝑉bp𝑒
−𝛽Δ𝐺      (8) 






      (9) 
Combining Eq.2, 4, 6 and 7 we can now derive an expression for the dissociation constant 
of the entire multivalent Qβ capsid. 
𝐾d = [∑
∫ 𝑑rQβ ∫ 𝑑𝜔Qβ𝑁(𝑖)[
2
3
∑ ∑ ∏ 𝑃str(r𝑘,𝑛)+
1
3












      (10) 
We evaluate the integrals over 𝐫Q𝛽 and 𝝎Q𝛽 in Eq.10 numerically by Monte Carlo 
integration. We thereby model the receptor as a planar surface on which the binding pockets 
form an equilateral triangle. Furthermore, we impose that the midpoint of the Qβ capsid, 
which we describe as a sphere with a diameter of 25 nm, cannot penetrate the receptor plane. 
In Supplementary Figure 2j we show the inverse of the dissociation constant 𝐾D
−1 (Eq. 10), 
since it allows to disentangle the contributions from mono-, di- and trivalently bound Qβ 
capsids. The angular restriction factor is set to 𝜔Sia=0.05. The stretching probability 𝑃str is 
obtained from molecular dynamics simulation (Eq.13). The contribution of all Sia duplets 
(green line) is summed up, while for Sia triplets (red lines) the contribution of each triplet 
(Supplementary Figure 2d) is shown individually. As we can see from Supplementary 
Figure 2j the binding behavior of the Qβ capsids is dominated by the two smallest Sia 
triplets. Both triplets occur in the hexagonal as well as pentagonal substructure of the capsid 
(Supplementary Figure 2d). To quantify the impact of trivalently bound capsids, we 
compare the dissociation constant taking all binding modes into account (inverse of the black 
line in Supplementary Figure 2d), denoted by 𝐾all , and the dissociation constant 
considering only the contribution of the two smallest Sia triplets (inverse of the sum over the 
solid and dashed red lines in Supplementary Figure 2j), denoted by 𝐾tri. We find that the 
ratio 𝛾 = (𝐾tri − 𝐾all)/𝐾all varies between γ = 4 ∙ 10
−6 for n=1 and γ = 0.15 for n=10. 
Hence, the dissociation constants differ by less than 15%, even for the longest EG linkers. 










,      (11) 
where the factor 60 in the denominator accounts for the fact that we find 60 Sia triplets with 
an edge length of 𝑑1=5.0 nm and 60 Sia triplets with an edge length of 𝑑2=5.9 nm on the 
capsid surface. The integral over the capsid position and orientation leads to the cooperativity 
factor 𝐶3, with 





𝑃str(𝐫𝑘, 𝑛) .     (12) 
Comparison of different virus strains: 
To compare the distance between neighboring binding pockets, for various virus strains, we 
calculate the distance between the C2 atoms of the Sia unit of a H1-(pdb: 1rvz), H3-(pdb-
entry: 1hgg) and a H5-(pdb: 5e2z) hemagglutinin. We find that within these three structures, 
the distance between the binding pockets varies by less than 2Å. With regard to the vertical 
position of the binding pockets, we find that in all three structures residue 159 (159Gly for 
1rvz, 159Ser for 1hgg, 159Asn for 5e2z) exhibits the largest vertical distance, with respect 
to the C-position, from the plane spanned by the Sia units. The vertical distance between 
residue 159 and the Sia units varies between 1.2nm for the H3-structure and 1.5nm for the 
H5-structure. Hence, the variation for the binding pocket position, in the range of 2-3Å, is 
smilingly small, but in the same range as the average linker length fluctuations of short EG 
linkers with less than five units (Supplementary Figure 2o). The combination of slight 
variations in the binding pocket position and the limited fluctuation range of short EG 
linkers, might explain, why virus strains including H3 receptors show optimal inhibition for 
Q[Sia1], while virus strains including H1 receptors exhibit optimal inhibition for Q[Sia3] 
and Q[Sia5]. Another parameter that slightly varies between different virus strains is the 
monovalent dissociation constant 𝐾mono. The impact of 𝐾mono on the dissociation constant 
𝐾d is shown in Supplementary Figure 2i. A slight increase of 𝐾mono by a factor of 1.5 
causes the dissociation constant 𝐾d to exceed values of 100nM for EG linkers with more 
than two EG units.  
Steric shielding: 
In the following we describe a simple estimate for the number of Qβ capsids necessary to 
inhibit an entire virus. Due to its size and spherical shape, a Qβ capsid can effectively shield 
an area on the virus surface that is much larger than the area of direct contact. Describing 
the Qβ capsid as a sphere with radius 𝑅c = 12.5 nm and the virus as a sphere with radius 𝑅v = 














       (14)
 
According to (Eq.13) and (Eq.14) the number of Qβ capsids per virus varies between 𝑁min= 
6 and 𝑁max = 50. The minimal number 𝑁min refers to a capsid arrangement with a maximal 
separation between the capsids that still inhibits the attachment of the virus to a planar 
surface (Supplementary Figure 2k). The maximal number 𝑁max corresponds to a random 






Number of HA spikes interacting with a single Qβ capsid: 
To quantify the interaction between a capsid and the virus, the contact area between the two 
binding partners has to be estimated. If the virus is flexible enough to wrap around the capsid, 
several HA trimers can participate in the binding process. In contrast, if the virus remains in 
a spherical shape, the interaction is limited to a single HA trimer.  
In Supplementary Figure 2k the deformation of a virus, bound to a spherical capsid, is 
depicted schematically. The larger the indentation depth 𝑑, the larger becomes the 
deformation energy as well as the contact area 𝐴c. Whereby, the contact area is given by 
𝐴c = 2𝜋𝑅c𝑑, with 𝑅c the radius of the capsid. Based on AFM-measurements Li et al.
58 
determined a linear relation between deformation force and indentation depth 𝑑, with a force 
constant of 𝑘=27.4 pN/nm for a virus of diameter 100 nm. The free energy 𝐹 of the deformed 
virus can be estimated as:  
𝐹 = −𝑔𝐴c +
𝑘
2
𝑑2       (15) 
The first term accounts for the binding energy, with 𝑔 the binding energy per area and the 
second term describes the elastic deformation. 
We assume an average distance between neighboring HA-trimers58 of 𝐷HA = 10 nm and a 
binding energy60 per HA-binding pocket of Δ𝐺 = 20𝑘B𝑇. If all three binding pockets are 
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2𝑘       (17)
 
With a capsid radius 𝑅c = 12.5 nm an indentation depth 𝑑 ≈ 2.2 nm is obtained, or 
equivalently a contact area of 𝐴c = 172 nm
2. For comparison, the area per HA-trimer is 
estimated by 𝜋(𝐷HA)
2 = 157 nm2. Comparing the contact area and the area per HA-trimer, 
we conclude that the interaction between virus and capsid is limited to single HA-trimers. 
Angular restriction factor - MD simulation: 
Based on the experimental data (Figure 3c in the main text) we fit Eq. 11 with an angular 
restriction factor of 𝜔𝑠𝑖𝑎=0.05. To verify that this value is determined by the angular space 
available to the Sia unit, we perform molecular dynamics (MD) simulations of a single Sia 
unit connected to a -CH2-CH2-O-CH3 linker. The Euler angles φ, θ, ψ that describe the 
orientation of the Sia unit relative to the linker are shown schematically in Supplementary 
Figure 2m. Scatterplots of the φ −  ψ, φ − θ and  ψ − θ angles obtained over a simulation 
time of 200ns are shown in Supplementary Figure 2n.  

















As we can see from Supplementary Figure 2n, θ is always restricted to values 54°< θ<70° 
(indicated as dashed lines in Supplementary Figure 2n) independent of the φ and ψ. Hence, 
the angular restriction factor factorizes into 





    (15) 
To determine the integral over φ and ψ numerically, each axis in the φ-ψ-scatterplot is 
divided into 70 equally distant bins, dividing the φ-ψ-plane into 4900 equally sized grid 
fields. The sum over the area of all grid fields containing at least one data point is equivalent 
to the integral over φ and ψ. Based on the scatterplot in Supplementary Figure 2n, we 
obtain a value of 𝜔𝑠𝑖𝑎=0.041, which is in good agreement with the fitted value of 𝜔𝑠𝑖𝑎=0.05. 
The difference between the fitted and the simulated value might arise due to a slightly 
repulsive interaction between the linker and the receptor in the range of 
ln(0.05/0.041)kBT=0.2 kBT per linker. 
EG linker - MD simulation: 
The Sia units are connected to the capsid via EG linkers. The EG length and extensibility 
significantly influences the binding behavior. We perform molecular dynamic simulation of 
short EG oligomers (CH3-O-[CH2-CH2-O-]n-CH3, with 𝑛 ∈ [1,10]) in water and determine 
the probability distribution 𝑃str(𝑟𝑒𝑡𝑒) of the end-to-end distance 𝑟𝑒𝑡𝑒. The end-to-end distance 
is measured between the outermost oxygen atoms. In Supplementary Figure 2o the 
stretching probability 𝑃str(𝑟𝑒𝑡𝑒) is shown for all EG oligomers. The stretching probability is 
normalized by the condition: 4𝜋∫ 𝑑𝑟ete𝑟ete








]       (16) 
The fit parameters 𝜇 and 𝜎 are indicated in the legend of Supplementary Figure 2o.  
 
Molecular dynamics (MD) simulations 
The MD simulations of EG oligomers in water are performed with the GROMACS 
simulation package61 version 4.6.8. The following simulation parameters are used: The time 
step is set to 2 fs. The temperature is set to 300 K. For temperature-/pressure coupling the v-
rescale62/Parrinello-Rahman63 algorithm with a relaxation time of 0.1 ps/0.5 ps is chosen. 
The pressure is set isotropically to 1 bar with a water compressibility of 4.5·10-5bar-1. All 
simulations are performed with periodic boundary conditions in all three directions. The cut-
off of non-bonded interactions is set to 1.0 nm. Long range electrostatic interactions are 
treated with the PME64,65 method. The length of all covalently bound hydrogen bonds is 
fixed via a LINCS66 algorithm, with a LINCS-order=4 and iteration number 1. The EG 
oligomers as well as the Sia unit connected to an EG-linker are solvated in tip3p water67. 
Cubic simulation boxes are used for all simulations. For the EG oligomers the initial edge 
size varies between 2.3nm and 6.2nm. For the Sia unit connected to an EG-linker the initial 
edge size is set to 3.5nm. To determine the end-to-end-distance distribution of individual EG 
oligomers the following simulation steps are performed: After an energy minimization a 
200 ns NPT-simulation is performed. The first 10 ns are discarded in the analysis. To 
determine the angular restriction factor the following simulation steps are performed: After 
an energy minimization a 202ns NPT-simulation is performed. The first 2 ns are discarded 
in the analysis. The EG oligomers and EG linkers, respectively are parametrized with the 
charmm35r forcefield68,69. The Sia units are parametrized with the charmm carbohydrate 
forcefield69. The bonds, angles and dihedrals at the connection between Sia and the EG linker 






Osia-Cpeg  →  OCE-CCT2 (charmm35r) 
Angles: 
Csia -Osia-Cpeg  →  CCT2-OCE-CCT2 (charmm35r) 
Osia-Cpeg-Hpeg  →  OCE-CCT2-HCT2 (charmm35r) 
Osia-Cpeg-Cpeg  →  OCE-CCT2-CCT2 (charmm35r) 
Dihedrals: 
Csia - Csia -Osia-Cpeg  →  CCT2- CCT2-OCE-CCT2 (charmm35r) 
Osia - Csia -Osia-Cpeg  →  CCT2- CCT2-OCE-CCT2 (charmm35r) 
Csia -Osia-Cpeg -Hpeg  →  CCT2-OCE-CCT2-HCT2 (charmm35r) 
Csia -Osia-Cpeg -Cpeg  →  CCT2-OCE-CCT2-CCT2 (charmm35r) 
Osia-Cpeg -Cpeg-Opeg →  OCE-CCT2-HCT2-OCE (charmm35r) 
The atom names follow the nomenclature in reference 68. 
 
Structure Optimization: 
To superimpose the structure of the HA receptor and the Qβ capsid, we first align their 
crystal structures, such that the C2 atoms of the Sia units as well as the anchoring points of 
the EG linkers on the Qβ capsid (residue 16) lie in parallel planes. Subsequently the 
structures are rotated such that the triangles formed on the HA receptor as well as on the Qβ 
capsid are orientated in parallel. From a first structure optimization of one Sia unit connected 
to a linker with one EG unit, we obtain the optimal height separation between the HA 
receptor and the Qβ capsid. The second structure optimization includes all three Sia units, 
residue 16 from the Qβ capsid and the linker between them. The coordinates of the Sia units 
as well as residue 16 are taken from the crystal structure. Furthermore, the coordinates of the 
Sia units and residue 16 are fixed and only the positions of the linker atoms are left to 
optimize. In the final step the crystal structure of the HA receptor, the crystal structure of the 
Qβ capsid and the optimized linker structure are superimposed. All structure optimizations 









Fig. S 1: Microscale thermophoresis of octadecyl rhodamine B chloride (r18) labeled A/X31. (a) Binding 
curves from experiments with Qβ[Sia1,3,5,8] and the control Qβ[Gal3] towards X31. The errors indicate the 
SEM (N≥3)  from  independent dilution preparations (a), Change in fluorescence during thermophoresis from 
dilution series either of Qβ[Gal3] phage capsids against X31 (b), or Qβ[Sia1] phage capsids against X31 (c). 
Change in fluorescence was obtained from the difference between the indicated gates at the initial fluorescence 
(blue gate) before start of thermophoresis and 5 s after the start (red gate) within the thermophoresis process. 
5.2 Qβ[Hpg] 
 







Fig. S 3: Deconvoluted ESI-MS spectrum of Qβ[Hpg]. 
 
Fig. S 4: MS/MS Fragment spectrum of the diagnostic peptide that carries the incorporated Hpg at position 16 
of the coat protein sequence. 
Q[Hpg]       Mcalc = 14104 
Q[K16M]    Mcalc = 14126 











Fig. S 5: Deconvoluted ESI-MS spectrum of Qβ[Gal3]. 
 
Fig. S 6: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired Gal modification at 








Q[Gal3]     Mcalc = 14482 
Q[K16M]   Mcalc = 14126 
























Q[Sia0]   Mcalc = 14438 









Fig. S 8. Deconvoluted ESI-MS spectrum of Qβ[Sia1]. 
 
Fig. S 9: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired Sia1 modification at 





Q[Sia1]       Mcalc = 14482 
Q[Sia1]-Sia Mcalc = 14190 
Q[K16M]     Mcalc = 14126 











Fig. S 10: Deconvoluted ESI-MS spectrum of Qβ[Sia3]. 
 
Fig. S 11: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired Sia3 modification at 




Q[Sia3]       Mcalc = 14570 
Q[Sia3]-Sia Mcalc = 14278 
Q[K16M]    Mcalc = 14126 












Fig. S 12: Deconvoluted ESI-MS spectrum of Qβ[Sia5]. 
 
Fig. S 13: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired Sia5 modification at 
position 16 of the coat protein sequence. 
Q[Sia5]       Mcalc = 14658 
Q[Sia5]-Sia Mcalc = 14366 
Q[K16M]    Mcalc = 14126 













Fig. S 14: Deconvoluted ESI-MS spectrum of Qβ[Sia8]. 
 
Fig. S 15: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired Sia8 modification at 
position 16 of the coat protein sequence. 
 
 
Q[Sia8]       Mcalc = 14790 
Q[Sia8]-Sia Mcalc = 14498 
Q[K16M]    Mcalc = 14126 












Fig. S 16: Deconvoluted ESI-MS spectrum of Qβ[2.6SL]. 
 
Fig. S 17: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired 2.6SL modification at 
position 16 of the coat protein sequence. 
Q[2.6SL]     Mcalc = 14762 
Q[K16M]    Mcalc = 14126 












Fig. S 18: Deconvoluted ESI-MS spectrum of Qβ[2.3SL]. 
 
Fig. S 19: MS/MS Fragment spectrum of the diagnostic peptide that carries the desired 2.3SL modification at 




Q[2.3SL]     Mcalc = 14762 
Q[K16M]    Mcalc = 14126 










5.11 NMR spectra 
1H-NMR of Gal3 (300 MHz, D2O): 
 
 







1H-NMR of Sia0 (300 MHz, D2O): 
 
 







1H-NMR of AcSia1 (300 MHz, CDCl3): 
 
 






1H-NMR of Sia1 (300 MHz, D2O): 
 
 







1H-NMR of AcSia3 (300 MHz, CDCl3): 
 
 







1H-NMR of Sia3 (300 MHz, D2O): 
 
 






1H-NMR of AcSia5 (300 MHz, CDCl3): 
 
 






1H-NMR of Sia5 (300 MHz, D2O): 
 
 






1H-NMR of AcSia8 (300 MHz, CDCl3): 
 
 







1H-NMR of Sia8 (300 MHz, D2O): 
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